Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

#4492

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Aim(s): To assess the clinical utility of NETest 2.0 in a large Swiss NEN cohort and validate its diagnostic accuracy (diagnostic algorithm) and prognostic ability to distinguish stable from progressive disease (prognostic algorithm).

Materials and methods: Consecutive patients with currently known or prior history of gastroenteropancreatic (GEP)-NEN (n=212), bronchopulmonary (BP)-NEN (n=29), and CUPs (n=26) were included. Disease persistence and status (stable or progressive) was determined by imaging (RECIST 1.1) and clinical evaluation. Blood samples for NETest 2.0 were collected from all 267 patients, deidentified, and measured blinded. Disease presence was defined as positive for scores ≥50, and progression as scores >40. Statistical analysis used Kruskal-Wallis, Mann-Whitney, and regression methods.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,